Introduction {#S0001}
============

Liver cancer ranks sixth in cancer incidence worldwide and second in tumor-related mortality worldwide, with more than half of the new cases and deaths now being reported in China.[@CIT0001] Hepatocellular carcinoma (HCC) is the predominant type of liver cancer and accounts for approximately 80% of liver cancer.[@CIT0002] In the past decade, the incidence and mortality of HCC has shown an upward trend in both males and females.[@CIT0003] Current treatment options for HCC patients include surgical resection, local ablation, and chemotherapy, and these have achieved certain therapeutic effects. However, these treatment options also cause side effects, such as high recurrence rates after surgical resection and local ablation[@CIT0004] and resistance to drugs, including sorafenib and regorafenib.[@CIT0005]--[@CIT0007] Therefore, identification of effective biomarkers and therapeutic strategies is imperative for improving the survival condition of HCC patients.

The rapid development of second-generation sequencing technology has raised awareness of epigenetic causes of human cancers. In particular, non-coding RNAs, such as long-chain non-coding RNAs (lncRNAs) have received wide attention. The lncRNAs are transcripts that are more than 200 nucleotides in length but cannot be translated into proteins.[@CIT0008] These non-coding RNAs play important roles in diverse human cancers and affect tumor biology activities including ranging from cell proliferation and cell to apoptosis.[@CIT0009]--[@CIT0011] One lncRNA, *MIR22HG*, has a reported involvement in the tumorigenesis of a variety of cancers. For example, silencing of *MIR22HG* triggered apoptosis in lung cancer cells, while upregulation of *MIR22HG* inhibited the proliferation of endometrial cancer cells.[@CIT0012],[@CIT0013] Studies have shown that overexpression of *MIR22HG* could significantly suppress the malignant progression of HCC, while indicating good survival outcome of HCC patients,[@CIT0014]--[@CIT0016] suggesting promising prospects for the application of *MIR22HG* in HCC treatment. Nevertheless, these studies had shortcomings, including the use of only limited numbers of HCC specimens for examining the expression level of *MIR22HG* in HCC and non-cancer tissues and the lack of sufficient diversity in the methods used to evaluate the expression of *MIR22HG* in HCC and non-cancer tissues. For these reasons, the exact molecular mechanism of *MIR22HG* in HCC has not yet been clarified.

In the present study, we performed a multidimensional assessment of the clinical significance of *MIR22HG* in an extremely large group of HCC samples by integrating data from in-house quantitative reverse transcription-polymerase chain reactions (qRT-PCR), RNA-sequencing, microarrays, and literature studies. Comprehensive indexes calculated from the present study, which included the standardized mean difference (SMD) and summarized receiver operating characteristic (SROC) curves, offered a relatively impartial evaluation of the differential expression of *MIR22HG* in HCC and non-cancer tissues. We also endeavored to uncover the molecular mechanism of *MIR22HG* in HCC by investigating the alterations in the profiles of *MIR22HG* in HCC, the transcription factors (TF) interacting with *MIR22HG*, the biological functions of the co-expressed genes of *MIR22HG*, and how nitidine chloride influences *MIR22HG* expression in HCC.

Materials And Methods {#S0002}
=====================

Clinico-Pathological Significance Of MIR22HG In HCC {#S0002-S2001}
---------------------------------------------------

### In-House qRT-PCR {#S0002-S2001-S3001}

HCC and paired non-cancer tissues were collected from March 2018 to March 2019 from 101 HCC patients, aged between 35 and 68 years (12 male and 8 female), who were treated at the First Affiliated Hospital of Guangxi Medical University (Nanning, China). The samples were fixed in 10% buffered formalin for 16 h and then paraffin embedded. All enrolled patients signed informed consent forms, and the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University approved the study.

The process of qRT-PCR has been described in detail in previous studies.[@CIT0017]--[@CIT0019] GAPDH served as the reference gene for *MIR22HG*. Information about the primers for *MIR22HG* and *GAPDH* is listed in [Table 1](#T0001){ref-type="table"}.[@CIT0018],[@CIT0019] MIR22HG expression was calculated by the formula:Table 1Information On The Primers For *MIR22HG* And *GAPDH*Sequence(5ʹ-\>3ʹ)Template StrandLengthStartStopTmGC%Self ComplementaritySelf 3ʹ ComplementarityForward primer\
for MIR22HGCCAGTTGAAGAACTGTTGCCCPlus2122924959.6652.386.001.00Reverse primer\
for MIR22HG\
Forward primer\
for GAPDHCGTATCATCCACCCTGCTGT\
AGTGGCAAAGTGGAGATTMinus2035033159.53553.000.00Reverse primer\
for GAPDHGTGGAGTCATACTGGAACA[^2]

2−ΔCq =−(CqMIR22HG-CqGAPDH)[@CIT0020]

### Evaluation Of The Clinicopathological Associations Of MIR22HG In HCC Using mRNA Data {#S0002-S2001-S3002}

In the present study, we obtained log~2~(x+0.001)-transformed level 3 transcripts per million reads (TPM) RNA-seq data from 374 HCC and 50 adjacent normal tissues, as well as the clinicopathological information, from The Cancer Genome Atlas (TCGA) data portal ([<https://portal.gdc.cancer.gov/>]{.ul}) (IBM Corp., Armonk, NY, USA). An additional 175 normal liver tissues from Genotype-Tissue Expression (GTEx) ([<https://www.gtexportal.org/home/>]{.ul}) were also included as the non-cancer control, giving mRNA-seq data from a total of 374 HCC and 225 non-cancer tissues.

### Integrated SMD Of MIR22HG Expression In HCC And Non-Cancer Tissues {#S0002-S2001-S3003}

Microarrays published before July 18, 2019 and pertaining to expression data for *MIR22HG* in HCC and non-cancer tissues were searched in the GEO ([<https://www.ncbi.nlm.nih.gov/gds/>]{.ul}) and ArrayExpress ([<https://www.ebi.ac.uk/arrayexpress/>]{.ul}) databases using the search terms "(C17orf91 OR MIR22HG OR MIR22 host gene) AND (hepato OR liver OR hepatic OR HCC) AND (adenocarcinoma OR carcinoma OR cancer OR neoplasm OR tumor OR tumor OR neoplas OR malignan)". Studies were included if they offered sufficient *MIR22HG* expression data (more than five HCC or non-cancer cases) in human HCC and non-cancer samples for the calculation of a SMD. Basic information, as well as expression data and data used to plot SROC curves, were extracted from the included studies according to methods described previously.[@CIT0021] Forest plots of SMDs with the 95% confidence interval (CI) were produced for in-house RT-qPCR data, mRNA-seq, and microarrays, as described previously.[@CIT0021] A series of plots, including SROC, forest plots of sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR), were created using MetaDisc v.1.4.

### Literature Study Selection For Comprehensive Analysis Of The Prognostic Value Of MIR22HG In HCC {#S0002-S2001-S3004}

In addition to the GEO and Arrayexpress databases, studies published as of July 18, 2019 were retrieved from literature databases, including PubMed, ScienceDirect, Ovid, Wiley Online Library, Web of Science, Springerlink, Embass, Chinese VIP, CNKI, Sinomed, and Wang Fang, to evaluate the prognostic significance of *MIR22HG* in HCC. The search terms for the literature searches were the same as those used for searching microarrays. Studies were included if they met the following requirements: (1) published in Chinese or English and (2) reporting sufficient data, including the hazard ratios (HRs) with 95% CIs for overall survival (OS) for HCC patients with different *MIR22HG* expression levels. Studies were excluded for the following reasons: (1) publication as letters, case reports, reviews, or conference reports and (2) incomplete prognostic data for *MIR22HG* in HCC. When duplicate study cohorts were encountered, only the most recent study was included. The first author, method for survival analysis, and HRs with 95% CIs were extracted from the qualified studies. HR values with 95% CIs for mRNA-seq, two microarrays (GSE76427 and E-MTAB-36), and all the included literature studies were merged using the meta package of R software v.3.5.2.

Potential Molecular Mechanism Of MIR22HG In HCC {#S0002-S2002}
-----------------------------------------------

### Gene Alteration Of MIR22HG In HCC Tissue From cBioPortal {#S0002-S2002-S3001}

The cBioPortal database ([<http://www.cbioportal.org>]{.ul}) was mined for mutation profiles of *MIR22HG* in HCC.[@CIT0022] The alteration status of *MIR22HG* in 440 TCGA provisional HCC samples was queried from the OncoPrint module of cBioPortal.

### Predicting MIR22HG--TF-mRNA Triplets In HCC {#S0002-S2002-S3002}

The interaction between TFs and lncRNAs contributed partly to the driving mechanism of HCC; therefore, we hypothesized that TFs might be involved in *MIR22HG*-related tumorigenesis of HCC. TFs that potentially could bind to *MIR22HG* were predicted through lncRNAMap. Correlation between the log2 (x+0.001) transformed transcripts per million (TPM) expression of *MIR22HG* and the predicted TFs in TCGA-HCC cohorts was assessed by Pearson correlation analysis in Graphpad Prism v.8.0.

### Co-Expression Analysis Of MIR22HG {#S0002-S2002-S3003}

We first calculated the differentially expressed genes (DEGs) based on the count data of 374 HCC and 50 adjacent normal samples from TCGA, which was performed using the limma voom package of R software v.3.5.2.[@CIT0023] Genes with a log2 fold change value \>1 or \<1 and an adjusted P value \<0.01 were defined as DEGs. We integrated the log2 (x+0.001) TPM expression value of DEGs and *MIR22HG* in 374 TCGA-HCC samples into an input matrix for subsequent co-expression analysis. Weighted correlation network analysis (WGCNA) was carried out utilizing the WGCNA package in R software v.3.5.2 for identification of genes that were co-expressed with *MIR22HG*. A co-expression network of *MIR22HG* and co-expressed genes was constructed in Cytoskape v.3.7 according to the calculated weight value of more than 0.05. We then analyzed the biological functions, pathways, and disease enrichment of the co-expressed genes using the ClusterProfiler package in R software v.3.5.2. Terms with P value \< 0.05 were considered statistically significant.

### The Impact Of Nitidine Chloride On Expression Of MIR22HG In HCC {#S0002-S2002-S3004}

Our team is researching the anti-cancer effect and mechanism of traditional Chinese medicines. Specifically, considerable research data have been accumulated for nitidine chloride, and we have found an inhibitory effect of nitidine chloride on the growth of liver cancer cells.[@CIT0024],[@CIT0025] Taking into account the clinico-pathological action of *MIR22HG* in HCC, we hypothesized that it might be affected by traditional Chinese medicines such as nitidine chloride. Therefore, we performed in vivo experiments on nude mice to investigate the influence of nitidine chloride on *MIR22HG* expression in HCC. Male and female nude mice, purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China), were handled according to the Guide for the Care and Use of Laboratory Animals (the Shanghai SLAC Laboratory Animal of China, 2015). Each mouse was inoculated with SMMC7721 cells (1 × 10^7^ cells/mL, 0.2mL in total) by subcutaneous injection into the right armpit. When the injected cells had produced a tumor of approximately 70 mm^3^ in size, all mice were randomly assigned to either the negative control group for intraperitoneal injection with saline or the treatment group for injection with 7 mg/kg nitidine chloride. After 15 days, the mice were anesthetized, and the tumor tissues were excised and stored at −80°C.

Total RNA was extracted with TRIzol Regent (Invitrogen, USA). RNA purity was determined using the NanoPhotometer^®^ spectrophotometer (IMPLEN, CA, USA). RNA integrity was checked using the RNA Nano 6000 Assay Kit of the Agilent Bioanalyzer 2100 system (Agilent Technologies, CA, USA).

The mRNA sequencing libraries were established using the rRNA-depleted RNA and the NEB Next^®^ Ultra™ Directional RNA Library Prep Kit for Illumina^®^ (NEB, USA), following the manufacturer's recommendations. The library quality was checked using the Agilent Bioanalyzer 2100 system. After removing reads with adaptors, \>5% unknown nucleotides, and low-quality bases, the qualified reads were mapped against human genome references (GRCh37/hg19). Differentially expressed lncRNAs were identified based on the count data of lncRNAs using DESeq2 package in R software v.3.3.2 (\|log2FC\|\>1, P\<0.01).

Statistical Analysis {#S0002-S2003}
--------------------

SPSS 22.0 was used for the statistical analyses of mRNA-seq and RT-qPCR data. The expression data for *MIR22HG* are presented as M ± SD. The expression levels of *MIR22HG* in HCC and non-cancer tissues determined by RT-qPCR were evaluated by paired sample *t*-tests and *MIR22HG* expression levels in HCC and non-cancer tissues from mRNA-seq were evaluated by independent samples *t*-tests. The significance of differential *MIR22HG* expression between two groups with different clinicopathological parameters was examined by independent samples *t*-tests. ROC curves were plotted to assess the discriminatory value of *MIR22HG* for HCC. AUC values of 0.5--0.7, 0.7--0.9, and 0.9--1.0 indicated a poor, moderate, and high discriminatory capacity, respectively. The prognostic significance of *MIR22HG* for HCC was examined by dividing all patient samples from mRNA-seq or microarrays (GSE76427 and E-MTAB-36) into two groups according to the median expression level of *MIR22HG*. Kaplan--Meier survival curves were drawn to compare the survival condition of patients with high or low *MIR22HG* expression. A P-value of less than 0.05 was considered statistically significant.

Results {#S0003}
=======

Clinico-Pathological Significance Of MIR22HG In HCC {#S0003-S2001}
---------------------------------------------------

### Differential Expression Of MIR22HG In HCC And Non-Cancer Tissues {#S0003-S2001-S3001}

Statistical analysis of RT-qPCR data for 101 HCC and paired non-cancer tissues demonstrated a significant downregulation of *MIR22HG* in HCC tissues compared with non-cancer tissues (P\<0.001) ([Table 2](#T0002){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). The expression of *MIR22HG* was also inversely correlated with metastasis and vascular invasion (P\<0.001 and P = 0.015) ([Table 2](#T0002){ref-type="table"}, [Figure 2](#F0002){ref-type="fig"}). MRNA-seq data for 374 HCC and 225 non-cancer samples also revealed the significant downregulation of *MIR22HG* in HCC (P\<0.001) ([Table 3](#T0003){ref-type="table"}) ([Figure 1](#F0001){ref-type="fig"}). A difference was also detected in the *MIR22HG* expression in groups of TCGA-HCC patients with various grades. Patients with advanced grade HCC (III--IV) had significantly lower expression of *MIR22HG* when compared with patients with early grade HCC (I--II) ([Table 3](#T0003){ref-type="table"}, [Figure 2](#F0002){ref-type="fig"}).Table 2Clinico-Pathological Value Of *MIR22HG* Expression In HCC From RT-qPCR DataClinico-Pathological FeatureNMIR22HG Relevant ExpressionM ± SDtPTissueCancer1010.752 ± 0.838−6.313\<0.001Non-cancer liver tissue1014.058 ± 5.197GenderMale800.707 ± 0.842−1.0440.299Female210.922 ± 0.823Age≥50510.930 ± 1.0232.2160.030\<50500.570 ± 0.547MetastasisYes520.480 ± 0.6133.540\<0.001No491.040 ± 0.949TNMIII-IV760.723 ± 0.8430.6000.550I-II250.839 ± 0.834EmbolusYes320.557 ± 0.5121.9590.053No690.842 ± 0.942NodesMultiple440.689 ± 0.8500.6530.515Single570.800 ± 0.834Vascular invasionYes380.512 ± 0.6442.4790.015No630.896 ± 0.911CapsularNo520.720 ± 0.8150.3940.695Yes490.786 ± 0.870CirrhosisYes470.854 ± 0.9221.1510.252No540.662 ± 0.756[^3][^4] Table 3Clinico-Pathological Value Of *MIR22HG* Expression In HCC From mRNA-Seq DataClinico-Pathological FeatureNMIR22HG Relevant ExpressionM ± SDtPTissueCancer3742.879 ± 0.948−8.63\<0.001Normal2253.678 ± 1.179GenderMALE2502.860 ± 0.954−0.8720.384FEMALE1212.951 ± 0.927Age\>601932.957 ± 0.9041.5140.131≤601772.808 ± 0.981StageIII-IV902.733 ± 1.0351.4860.138I-II2572.904 ± 0.905M stageM142.009 ± 0.6191.6480.101M02662.814 ± 0.973N stageN143.330 ± 1.497−1.0710.285N02522.808 ± 0.960T stageT3-4932.746 ± 0.9931.6470.100T0-22752.932 ± 0.926GradeG3-41342.734 ± 0.9912.3650.019G1-22322.976 ± 0.912[^5][^6] Figure 1MIR22HG expression in in-house RT-qPCR, mRNA-seq, and 17 of the included microarrays Violin plots display the differential expression levels of *MIR22HG* in non-cancer samples and HCC samples for in-house RT-qPCR, mRNA-seq and 17 of the included microarrays (GSE54238, GSE74656, GSE62232, GSE31370, GSE36376, GSE36411, GSE39791, GSE46444, GSE56140, GSE57727, GSE57957, GSE76427, GSE87630, GSE89377, GSE98617, GSE84402, and GSE76297) **(A-S)**.Figure 2Distribution of *MIR22HG* in different groups of clinical features (**A**) MIR22HG expression in groups of different ages from in-house RT-qPCR; (**B**) Metastasis status from in-house RT-qPCR; (**C**) Vascular invasion status from in-house RT-qPCR; (**D**) Clinical grades from mRNA-seq data.

The GEO and Arrayexpress searches retrieved a total of 34 GEO microarrays and three Arrayexpress microarrays with sufficient expression data for *MIR22HG* in more than five HCC and non-cancer samples; these were considered eligible for the integrated calculation of SMD. The basic information and extracted data for all the included microarrays is summarized in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}. *MIR22HG* showed a clearly downregulated expression in most of the microarrays (P\<0.05) ([Figures 1](#F0001){ref-type="fig"} and [3](#F0003){ref-type="fig"}). A panel of ROC curves for the in-house RT-qPCR, mRNA-seq, and all included microarrays suggested a good ability of *MIR22HG* to distinguish HCC from non-cancer tissues ([Figures 4](#F0004){ref-type="fig"} and [5](#F0005){ref-type="fig"}). The integrated SMD for the in-house RT-qPCR, mRNA-seq, and all included microarrays, which together covered an extremely large sample of 2636 HCC and 2072 non-cancer samples, corroborated the downregulated expression of *MIR22HG* in HCC (SMD = −0.97, 95% CI = −1.17- −0.77, I^2^ = 88%, P\<0.01) ([Figure 6](#F0006){ref-type="fig"}). Subgroup analysis revealed that experiment type might be a potential source of heterogeneity because the microarrays in the subgroup of transcription profiling by array showed no heterogeneity (I^2^ = 0%, P = 0.42) ([Figure 6B](#F0006){ref-type="fig"}). The sROC curves and forest plots of SEN, SPE, PLR, NLR, and DOR for in-house RT-qPCR, mRNA-seq and all included microarrays confirmed the moderate capability of *MIR22HG* to differentiate HCC from non-cancer tissues ([Figure 7](#F0007){ref-type="fig"}).Table 4Basic Information For All Included MicroarraysNumberStudyCancer NCancer MCancer SDNon-Cancer NNon-Cancer MNon-Cancer SDSample TypePlatformExperiment1GSE54238267.5851.004308.1341.003TissueGPL16955Non-coding RNA profiling by array2GSE7465656.5010.15056.6320.243TissueGPL16043Expression profiling by array3GSE31370150.8160.49751.0840.509TissueGPL10558Expression profiling by array4GSE363762406.3390.3741936.4170.302tissueGPL10558Expression profiling by array5GSE36411427.7990.152427.8550.155TissueGPL10558Expression profiling by array6GSE39791726.7440.108726.7560.126TissueGPL10558Expression profiling by array7GSE46444887.1491.515487.6601.511TissueGPL13369Expression profiling by array8GSE56140357.5250.383347.8850.307TissueGPL18461Expression profiling by array9GSE57727577.9320.75457.7000.505TissueGPL14951Expression profiling by array10GSE57957397.9550.464398.3460.681TissueGPL10558Expression profiling by array11GSE764271157.8230.518528.2100.437TissueGPL10558Expression profiling by array12GSE87630646.9180.482308.2480.527TissueGPL6947Expression profiling by array13GSE89377407.5360.670678.4190.463TissueGPL6947Expression profiling by array14GSE98617369.4581.2521310.1161.635TissueGPL14951Expression profiling by array15GSE84402146.0891.001147.5390.516TissueGPL570Expression profiling by array16GSE76297746.1600.385586.6830.259TissueGPL17586Expression profiling by array17GSE62232817.2030.712107.9830.389TissueGPL570Expression profiling by array18GSE60502188.9230.691189.9710.607TissueGPL96Expression profiling by array19GSE4640869.0690.36269.7880.378TissueGPL4133Expression profiling by array20GSE45436936.1150.929417.2360.693TissueGPL570Expression profiling by array21GSE45267465.9750.725417.1110.712TissueGPL570Expression profiling by array22GSE250972681.1790.8632892.4501.169TissueGPL10687Expression profiling by array23GSE14520-\
GPL571226.1230.636217.4810.479TissueGPL571Expression profiling by array24GSE255991313.2488.8481314.0862.516TissueGPL9052Expression profiling by high throughput sequencing25GSE773145010.2687.8125025.97511.265TissueGPL9052Expression profiling by high throughput sequencing26GSE124535357.9204.562358.2053.125TissueGPL20795Expression profiling by high throughput sequencing27GSE94660211.8730.717212.3940.544TissueGPL16791Expression profiling by high throughput sequencing28GSE56545308.1141.100299.8780.860TissueGPL15433Expression profiling by high throughput sequencing29GSE875922720.02718.2222619.24510.371TissueGPL11154Expression profiling by high throughput sequencing30GSE65485505.2803.00558.8982.688TissueGPL11154Expression profiling by high throughput sequencing31GSE69164116.4761.9641111.5526.135TissueGPL11154Expression profiling by high throughput sequencing32GSE63863126.1172.2471211.3775.880TissueGPL11154Expression profiling by high throughput sequencing33GSE8217787.5022.452199.1045.002TissueGPL11154Expression profiling by high throughput sequencing34GSE14520-\
GPL39212256.3890.7682207.5400.507TissueGPL3921Expression profiling by array35E-MTAB-\
150377.0380.617107.9230.876CellsHG-U133_Plus_2Transcription profiling by array36E-TABM-36576.0560.58456.7550.218TissueHG-U133ATranscription profiling by array37E-MTAB-9501197.4600.8341578.0340.889TissueHG-U133_Plus_2Transcription profiling by array[^7] Table 5Data Used To Plot The sROC Curves From All Included MicroarraysAccession NumberTPFPFNTNGSE54238262901GSE746565401GSE3137010145GSE363763419206174GSE36411214041GSE3979145362736GSE46444824464GSE56140203334GSE57727411164GSE57957393801GSE764271011452GSE87630643000GSE89377406700GSE98617351112GSE84402141400GSE76297107358GSE62232307810GSE60502181800GSE464086600GSE45436934100GSE45267464100GSE2509726828900GSE14520-GPL571222100GSE25599131300GSE77314505000GSE1245351382227GSE94660212100GSE56545302900GSE87592242036GSE6548510495GSE69164111100GSE63863121200GSE8217751039GSE14520_GPL392122522000E-MTAB-15035057E-TABM-36245330E-MTAB-95011915700[^8] Figure 3MIR22HG expression in 20 of the included microarrays Violin plots display the differential expression levels of *MIR22HG* in non-cancer samples and HCC samples for 20 of the included microarrays (GSE60502, GSE46408, GSE45436, GSE45267, GSE25097, GSE14520-GPL571, GSE25599, GSE77314, GSE124535, GSE94660, GSE56545, GSE87592, GSE65485, GSE69164, GSE63863, GSE82177, GSE14520_GPL3921, E-MTAB-1503, E-TABM-36, and E-MTAB-950) (**A-T**).Figure 4Discriminatory ability of *MIR22HG* in hepatocellular carcinoma (HCC) for in-house RT-qPCR, mRNA-seq, and part of the included microarrays A panel of ROC curves shows the discriminatory capacity of *MIR22HG* for HCC in in-house RT-qPCR, mRNA-seq, and part of the included microarrays (**A-S**).Figure 5Discriminatory ability of *MIR22HG* in hepatocellular carcinoma (HCC) for the other part of the included microarrays A panel of ROC curves shows the discriminatory capacity of *MIR22HG* for HCC in the other part of the included microarrays (**A-T**).Figure 6The integrated standardized mean difference (SMD) of *MIR22HG* expression in hepatocellular carcinoma (HCC) (**A**) Forest plot. (**B**) Sensitivity analysis. (**C**) Forest plot for the subgroup analysis. (**D**) Funnel plot.Figure 7Summarized receiver operating characteristic (SROC) curves for in-house RT-qPCR, mRNA-seq, and all included microarrays (**A**) SROC curves; (**B**) Forest plot of sensitivity; (**C**) Forest plot of specificity; (**D**) Forest plot of positive likelihood ratio; (**E**) Forest plot of negative likelihood ratio; (**F**) Forest plot of diagnostic odds ratio.

### The Prognostic Impact Of MIR22HG On HCC {#S0003-S2001-S3002}

Kaplan-Meier survival curves were plotted for mRNA-seq data and two microarray studies (GSE76427 and E-MTAB-36) containing overall survival data for *MIR22HG* in HCC ([Figure 8](#F0008){ref-type="fig"}). Three literature studies that provided overall survival data of *MIR22HG* were enrolled for comprehensive analysis of the prognostic significance of *MIR22HG* for HCC.[@CIT0015],[@CIT0016],[@CIT0026] Survival data extracted from the three included literature studies are listed in [Table 6](#T0006){ref-type="table"}. Pooled HRs incorporating overall survival data from mRNA-seq, two microarrays, and three literature studies implicated *MIR22HG* as a protective prognostic factor for HCC (HR = 0.75, 95% CI = 0.64--0.89, I^2^ = 64%, P\<0.01) ([Figure 9A](#F0009){ref-type="fig"}). Subgroup analysis and sensitivity analysis reported an unspecified cause of heterogeneity ([Figure 9B](#F0009){ref-type="fig"} and C). No significant publication bias was detected in the symmetrical funnel plot (P = 0.517) ([Figure 9D](#F0009){ref-type="fig"}).Table 6Summary Of Survival Data For The Comprehensive Prognostic Value Of *MIR22HG* In Hepatocellular Carcinoma (HCC)StudyYearHRLCIUCIMethodDong et al.20170.9523809520.5285412260.931966449Multivariate Cox regression analysisDong et al.20180.5109862030.3815337660.692520776Univariate Cox regression analysisZhang et al.20180.4960.270.912Multivariate Cox regression analysisZhang et al.20180.4090.2270.735Univariate Cox regression analysisWu et al.20180.790.680.92Multivariate Cox regression analysisWu et al.20180.80.680.94Univariate Cox regression analysisMRNA-seq20170.8895632240.7354811571.075925226Univariate Cox regression analysisGSE7642720181.636371160.7678581353.487246475Univariate Cox regression analysisE-TABM-3620140.7657102620.3736271761.569244002Univariate Cox regression analysis[^9] Figure 8Kaplan-Meier survival curves of *MIR22HG* for mRNA-seq and two microarray studies (**A**) Survival condition for patients from mRNA-seq group; (**B**) Survival condition for patients from GSE76427; (**C**) Survival condition for patients from E-MTAB-36.Figure 9Comprehensive analysis of the prognostic value of *MIR22HG* in hepatocellular carcinoma (HCC) (**A**) Forest plot; (**B**) Sensitivity analysis; (**C**) Subgroup analysis based on methods; (**D**) Funnel plot.

Potential Molecular Mechanism Of MIR22HG In HCC {#S0003-S2002}
-----------------------------------------------

### Gene Alteration Of MIR22HG In HCC Tissue From cBioPortal {#S0003-S2002-S3001}

Alteration profiles in cBioPortal indicated the occurrence of 18 cases of gene alteration, including two cases of amplification, seven cases of deep deletion, and nine cases of high mRNA, in TCGA provisional HCC samples, accounting for 5% of all the profiled cases ([Figure 11A](#F0011){ref-type="fig"}).

### Predicting MIR22HG-Transcription Factor (TF)-mRNA Triplets In HCC {#S0003-S2002-S3002}

A total of 22 *MIR22HG*-TF-mRNA triplets were predicted by lncRNAmap ([Table 7](#T0007){ref-type="table"}). Of the 22 TFs with potential relationships with *MIR22HG*, we found significant reverse correlation between *MIR22HG* and HNF4A expression (r = −0.097, P = 0.045) ([Figure 11B](#F0011){ref-type="fig"}).Table 7Predicted *MIR22HG*-TF-mRNA Triplets In Hepatocellular Carcinoma (HCC) From LncMAPLncRNA IDTF IDTF SymbolGene IDGene SymbolCorrelation Coefficient In lncRNA Low Expression GroupCorrelation Coefficient In lncRNA High Expression GroupScoreP valueFDRENSG00000186594ENSG00000005339CREBBPENSG00000052795FNIP20.760.2620.99900ENSG00000186594ENSG00000028277POU2F2ENSG00000096968JAK20.1480.6840.99900ENSG00000186594ENSG00000036549ZZZ3ENSG00000108298RPL19−0.582−0.07030.99500ENSG00000186594ENSG00000077463SIRT6ENSG00000169756LIMS1−0.674−0.1980.99600ENSG00000186594ENSG00000100393EP300ENSG00000052795FNIP20.8180.33100ENSG00000186594ENSG00000101076HNF4AENSG00000048740CELF20.101−0.597100ENSG00000186594ENSG00000109320NFKB1ENSG00000005100DHX330.6990.2230.99700ENSG00000186594ENSG00000113580NR3C1ENSG00000197958RPL12−0.721−0.1850.99900ENSG00000186594ENSG00000120837NFYBENSG00000160957RECQL4−0.603−0.0810.99600ENSG00000186594ENSG00000130522JUNDENSG00000118816CCNI−0.605−0.04060.99800ENSG00000186594ENSG00000137265IRF4ENSG00000118308LRMP0.2250.6930.99700ENSG00000186594ENSG00000140262TCF12ENSG00000005100DHX330.8960.394100ENSG00000186594ENSG00000147133TAF1ENSG00000065559MAP2K40.5510.09030.98700ENSG00000186594ENSG00000154727GABPAENSG00000111252SH2B30.5720.0970.99100ENSG00000186594ENSG00000156127BATFENSG00000000938FGR0.1050.6670.99900ENSG00000186594ENSG00000158773USF1ENSG00000170340B3GNT2−0.571−0.09480.99100ENSG00000186594ENSG00000169016E2F6ENSG00000079462PAFAH1B30.2770.814100ENSG00000186594ENSG00000169083ARENSG00000106560GIMAP20.5850.1140.99100ENSG00000186594ENSG00000169375SIN3AENSG00000052795FNIP20.6050.01420.99900ENSG00000186594ENSG00000170345FOSENSG00000020633RUNX30.06530.5970.99700ENSG00000186594ENSG00000184634MED12ENSG00000077348EXOSC5−0.538−0.001490.99500ENSG00000186594ENSG00000185591SP1ENSG00000005100DHX330.7480.12100[^10]

### Co-Expression Analysis Of MIR22HG {#S0003-S2002-S3003}

In total, 5942 DEGs were identified by limma voom analysis in TCGA-LIHC cohorts. The WGCNA for the expression matrix of these DEGs and *MIR22HG* showed co-expression of 59 genes with *MIR22HG* (weight value \>0.05) ([Figure 12](#F0012){ref-type="fig"}). Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis for co-expressed genes of *MIR22HG* disclosed their main enrichment in molecular functions that included protein tyrosine kinase activity, non-membrane spanning protein tyrosine kinase activity, and phosphotyrosine residue binding, as well as clustering in pathways that included osteoclast differentiation, chemokine signaling pathways, and hematopoietic cell lineage (P\<0.05) ([Figures 13A](#F0013){ref-type="fig"}-C and 14). The co-expressed genes were associated with several diseases, including human immunodeficiency virus infectious disease, gout, and primary immunodeficiency disease (P\<0.05) ([Figure 13D](#F0013){ref-type="fig"}).

### Differentially Expressed lncRNAs In Nitidine Chloride Treated HCC Xenografts {#S0003-S2002-S3004}

After the quality control of principal component analysis, two NC-treated and three control HCC xenograft tumor tissues were collected for detection of differentially expressed lncRNAs. The tumor volumes in the NC-treated group were significantly reduced compared with those of control group (p-value \< 0.05).[@CIT0027] Heatmaps for differentially expressed lncRNAs before and after the nitidine chloride treatment in HCC xenografts showed a significant upregulation of 23 lncRNAs and downregulation of 12 lncRNAs. In particular, *MIR22HG* was significantly upregulated in nitidine chloride-treated HCC xenograft tissues (log2FC = 1.373, P\<0.001) ([Figure 10](#F0010){ref-type="fig"}).Figure 10Heatmap of differentially expressed lncRNAs in nitidine chloride-treated hepatocellular carcinoma (HCC) xenografts The expression changes of differentially expressed lncRNAs between before and after nitidine chloride treatment in HCC xenografts are displayed in squares of colors ranging from green to red.Figure 11Gene alteration of *MIR22HG* in hepatocellular carcinoma (HCC) tissue and correlation between *MIR22HG* and one of the predicted transcription factors (**A**) Gene alteration of *MIR22HG* in HCC tissue from cBioPortal; (**B**) Correlation diagram of *MIR22HG* and HNF4A expression.Figure 12Co-expression network of *MIR22HG* in hepatocellular carcinoma (HCC) MIR22HG and its co-expressed genes are marked in red and yellow, respectively. The width of the links between genes represent the value of the weights.Figure 13Gene ontology and disease ontology analysis for genes co-expressed with *MIR22HG* (**A**) Emapplot for significant terms of biological functions; (**B**) Emapplot for significant terms of cellular component; (**C**) Emapplot for significant terms of molecular functions; (**D**) Emapplot for significant terms of diseases.Figure 14Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis for co-expressed genes of *MIR22HG* Enrichment of co-expressed genes in significant KEGG pathway terms were visualized as a chord plot composed of ribbons.

Discussion {#S0004}
==========

The novelties of this article are reflected in the following aspects. We integrated data from in-house RT-qPCR, RNA-sequencing, microarray, and literature studies to provide a comprehensive evaluation of the clinico-pathological and prognostic significance of *MIR22HG* in an extremely large group of HCC samples. We explored the potential mechanism of *MIR22HG* in HCC by analyzing the alteration profiles of *MIR22HG* in HCC, by predicting TFs interacting with *MIR22HG*, and by annotating the biological functions of genes co-expressed with *MIR22HG*. We also compared the expression of *MIR22HG* in HCC nude mice xenografts before and after a treatment with nitidine chloride.

When our study is compared with several previous studies that explored the role of *MIR22HG* in HCC using a single method, one of the highlights of our study is that we conducted a comprehensive appraisal of the clinical significance of *MIR22HG* in HCC using an extremely large number of samples (2636 HCC and 2072 non-cancer tissues) collected from in-house RT-qPCR, RNA-seq, microarrays, and literature studies. The huge size of our sample group strengthened the reliability of our results. We confirmed downregulation of *MIR22HG* in HCC, the correlation between *MIR22HG* expression and the malignant phenotype of HCC, and the beneficial prognostic influence of *MIR22HG* on HCC, in agreement with the reports by prior research groups.[@CIT0014]--[@CIT0016] These results implied that downregulation of *MIR22HG* results in a loss of its protective effect in HCC and subsequent malignant progression of the tumor, which is no longer restrained by *MIR22HG*. Consequently, HCC patients with low *MIR22HG* expression are predicted to show worse survival.

The finding that *MIR22HG* is downregulated in HCC then raises the question of the nature of the mechanism directing the *MIR22HG* effects on HCC. Previous studies revealed that *MIR22HG* could regulate the miR-10a-5p/NCOR2 axis, HMGB1, or HuR to participate in the oncogenesis of HCC.[@CIT0014],[@CIT0015] Our investigation of the molecular basis of *MIR22HG* in HCC also provided novel insights into the mechanism of *MIR22HG* in HCC. The finding of seven cases of deep deletion occurring in the TCGA provisional HCC samples from cBioPortal may explain the downregulation of *MIR22HG* at the transcriptional level. The predicted *MIR22HG*-TF-mRNA triplets in HCC hinted that a binding reaction between *MIR22HG* and TFs, such as *CREBBP, POU2F2, ZZZ3, SIRT6*, and *EP300*, might participate in the initiation and development of HCC. Co-expression analysis for *MIR22HG* implicated the *MIR22HG*-related gene interaction network in HCC.

Several of the genes co-expressed with *MIR22HG*, including *NLRP3, CSF1R, SIGLEC10*, and *ZEB2*, were reported to play crucial roles in the initiation and progression of HCC.[@CIT0028]--[@CIT0031] Functional analysis of the co-expressed genes suggested a significant enrichment in molecular functions that included protein tyrosine kinase activity, non-membrane spanning protein tyrosine kinase activity, and phosphotyrosine residue binding, as well as activation of pathways involving hematopoietic cell lineage, viral protein interaction with cytokines and cytokine receptors, and activity of the Rap1 signaling pathway. We noted that the Rap1 signaling pathway was closely associated with the growth, invasion, and apoptosis of HCC cells. Mo et al reported that *EYA4* could attenuate the growth and invasion of HCC cells by repression of the NF-κB activity and *RAP1* expression.[@CIT0032] In vitro experiments by Zha et al showed that knockdown of Rap1 led to 5-fluorouracil-induced apoptosis in HepG2 cells.[@CIT0033] We postulated that the co-expressed genes may coordinate with *MIR22HG* to influence molecular functions and pathways essential for the oncogenesis of HCC, thereby affecting the development of HCC.

Unlike studies that investigated the mechanism of *MIR22HG* in HCC by focusing on the interplay between *MIR22HG* and specific miRNAs or mRNAs, our study has uncovered a new mechanism for *MIR22HG* in HCC using traditional Chinese medicine as the breakthrough point. Nitidine chloride is a natural alkaloid compound with proven anti-tumor effects in multiple human cancers, including osteosarcoma, ovarian cancer, acute myeloid leukemia, and HCC.[@CIT0025],[@CIT0034]--[@CIT0036] The impact of nitidine chloride on lncRNAs in cancer has never been studied previously, so we conducted in vivo experiments to test whether nitidine chloride treatment might influence the expression of *MIR22HG* in HCC. The results demonstrated that nitidine chloride could stimulate *MIR22HG* expression in HCC xenografts, thereby implying that nitidine chloride and *MIR22HG* might have synergistic effects in the inhibition of HCC tumor growth.

The present study had several limitations that should be pointed out. The effect of *MIR22HG* on the function of HCC cells should be validated by in vitro or in vivo experiments. Limited by experiment support, expression of lncRNAs was sequenced in only three control and two NC-treated groups, which should be conducted with larger sample size. The interactions between *MIR22HG* and the predicted TFs, the co-expressed genes, and nitidine chloride also require further experiments. Further work is warranted to address these limitations.

Conclusion {#S0005}
==========

In conclusion, we identified downregulation of *MIR22HG* and a protective effect of *MIR22HG* on the clinical progression and prognosis of HCC patients.

The authors would like to thank TCGA, Arrayexpress, GEO, cBioPortal and LncMAP databases for the availability of the data.

Ethics Approval And Informed Consent {#S0006}
====================================

All 101 patients with HCC provided signed informed consent and approval of this study was granted by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. Approval for the use of nude mice in this study was granted by the Ethical Committee of First Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi, China) (2018-KY-NSFC-102).

Data Availability {#S0007}
=================

The datasets generated and/or analyzed during the current study are available in TCGA ([<https://portal.gdc.cancer.gov/>]{.ul}), Arrayexpress ([<https://www.ebi.ac.uk/arrayexpress/>]{.ul}), GEO ([<https://www.ncbi.nlm.nih.gov/gds/>]{.ul}), cBioPortal ([<https://www.cbioportal.org/>]{.ul}), and LncMAP ([<http://bio-bigdata.hrbmu.edu.cn/LncMAP/survival.jsp>]{.ul}).

Disclosure {#S0008}
==========

All authors declared no conflicts of interests in this work.

[^1]: These authors contributed equally to this work

[^2]: **Abbreviation:** Tm, melting temperature.

[^3]: **Notes:** Unpaired and paired sample *t*-test was performed to evaluate the clinico-pathological parameters of HCC. P\<0.05 was considered statistically significant.

[^4]: **Abbreviations:** N, number; M, mean; SD, standard deviation.

[^5]: **Notes:** Unpaired sample *t* test was performed to evaluate the clinico-pathological parameters of HCC. P\<0.05 was considered statistically significant.

[^6]: **Abbreviations:** N, number; M, mean; SD, standard deviation.

[^7]: **Abbreviations:** N, number; M, mean; SD, standard deviation.

[^8]: **Abbreviations:** TP, true positivity; FP, false positivity; FN, false negativity; TN, true negativity.

[^9]: **Abbreviations:** HR, hazard ratio; LCI, lower confidence interval; UCI, upper confidence interval.

[^10]: **Abbreviations:** TF, transcription factor; FDR, false discovery rate.
